Literature DB >> 29025958

miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Balabhadrapatruni V S K Chakravarthi1,2, Darshan S Chandrashekar1, Sumit Agarwal1, Sai Akshaya Hodigere Balasubramanya1, Satya S Pathi3, Moloy T Goswami3, Xiaojun Jing3,4, Rui Wang3, Rohit Mehra3,4,5, Irfan A Asangani3, Arul M Chinnaiyan3,4,5,6,7, Upender Manne1,2, Guru Sonpavde8, George J Netto1, Jennifer Gordetsky1, Sooryanarayana Varambally9,2,3.   

Abstract

In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and tumor metastasis. Here, it was found that the expression of STMN1 RNA and protein is elevated in metastatic prostate cancers. Knockdown of STMN1 resulted in reduced proliferation and invasion of cells and tumor growth and metastasis in vivo Furthermore, miR-34a downregulated STMN1 by directly binding to its 3'-UTR. Overexpression of miR-34a in prostate cancer cells reduced proliferation and colony formation, suggesting that it is a tumor suppressor. The transcriptional corepressor C-terminal binding protein 1 (CtBP1) negatively regulated expression of miR-34a. Furthermore, gene expression profiling of STMN1-modulated prostate cancer cells revealed molecular alterations, including elevated expression of growth differentiation factor 15 (GDF15), which is involved in cancer progression and potentially in STMN1-mediated oncogenesis. Thus, in prostate cancer, CtBP1-regulated miR-34a modulates STMN1 expression and is involved in cancer progression through the CtBP1\miR-34a\STMN1\GDF15 axis.Implications: The CtBP1\miR-34a\STMN1\GDF15 axis is a potential therapeutic target for treatment of aggressive prostate cancer. Mol Cancer Res; 16(7); 1125-37. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29025958      PMCID: PMC5897228          DOI: 10.1158/1541-7786.MCR-17-0230

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  83 in total

1.  siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines.

Authors:  Yuwen Song; Luyan Mu; Xuezhe Han; Xiaoqian Liu; Songbin Fu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2014-10-27       Impact factor: 3.848

2.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

3.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Analysis of phosphoprotein p19 by liquid chromatography/mass spectrometry. Identification of two proline-directed serine phosphorylation sites and a blocked amino terminus.

Authors:  J E Labdon; E Nieves; U K Schubart
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

6.  Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2.

Authors:  L Beretta; T Dobránsky; A Sobel
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

7.  MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  O M Fisher; A J Levert-Mignon; S J Lord; K K M Lee-Ng; N K Botelho; D Falkenback; M L Thomas; Y V Bobryshev; D C Whiteman; D A Brown; S N Breit; R V Lord
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

8.  MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.

Authors:  B V S K Chakravarthi; M T Goswami; S S Pathi; A D Robinson; M Cieślik; D S Chandrashekar; S Agarwal; J Siddiqui; S Daignault; S L Carskadon; X Jing; A M Chinnaiyan; L P Kunju; N Palanisamy; S Varambally
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

9.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

10.  Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo.

Authors:  Jiwen Wang; Yanli Yao; Yue Ming; Sheng Shen; Nan Wu; Jiaqi Liu; Han Liu; Tao Suo; Hongtao Pan; Dexiang Zhang; Kan Ding; Houbao Liu
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

View more
  23 in total

1.  Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.

Authors:  Jinghui Li; Xiaoyu Liu; Yu Qiao; Renli Qi; Shunjin Liu; Jing Guo; Yang Gui; Juanjuan Li; Hualin Yu
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

Review 2.  Interaction between prostate cancer stem cells and bone microenvironment regulates prostate cancer bone metastasis and treatment resistance.

Authors:  Lu Yao; Xiangyu Zhang
Journal:  J Cancer       Date:  2022-06-13       Impact factor: 4.478

Review 3.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

4.  A novel rapid quantitative method reveals stathmin-1 as a promising marker for esophageal squamous cell carcinoma.

Authors:  Lu Yan; Xiu Dong; Jiajia Gao; Fang Liu; Lanping Zhou; Yulin Sun; Xiaohang Zhao
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

5.  Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA.

Authors:  Merle Hanke; Josephine Dubois; Ingo Kausch; Sonja Petkovic; Georg Sczakiel
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

6.  PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression.

Authors:  Sumit Agarwal; Balabhadrapatruni V S K Chakravarthi; Hyung-Gyoon Kim; Nirzari Gupta; Kevin Hale; Sai Akshaya Hodigere Balasubramanya; Patsy G Oliver; Dafydd G Thomas; Isam-Eldin A Eltoum; Donald J Buchsbaum; Upender Manne; Sooryanarayana Varambally
Journal:  Transl Oncol       Date:  2020-05-15       Impact factor: 4.243

7.  MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4.

Authors:  Chun-Wen Cheng; Wen-Ling Liao; Po-Ming Chen; Jyh-Cherng Yu; Hui-Ping Shiau; Yi-Hsien Hsieh; Huei-Jane Lee; Yu-Chun Cheng; Pei-Ei Wu; Chen-Yang Shen
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

Review 8.  MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer.

Authors:  Valentina Doldi; Rihan El Bezawy; Nadia Zaffaroni
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer.

Authors:  Guangsu Xun; Wei Hu; Bing Li
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

10.  PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer.

Authors:  Sumit Agarwal; Balabhadrapatruni V S K Chakravarthi; Michael Behring; Hyung-Gyoon Kim; Darshan S Chandrashekar; Nirzari Gupta; Prachi Bajpai; Amr Elkholy; Sai A H Balasubramanya; Cherlene Hardy; Sameer Al Diffalha; Sooryanarayana Varambally; Upender Manne
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.